Inify Laboratories - Strong market interest and launch on track
STOCKHOLM – April 26th, 2023 – Inify Laboratories, a fully integrated digital ultramodern laboratory service that provides cancer diagnostics within pathology, is on track for launch at the end of Q2 this year.
“We continue to make good progress with our laboratory. This first quarter has been dominated by work with installation, testing and documentation, to get the laboratory ready to serve public and private clinics with prostate cancer diagnostics,” says CEO Fredrik Palm at Inify Laboratories.
The company sees great interest from potential customers, and has received positive feedback after attending several market and educational events.
“The interest among upcoming customers remains strong. We have deepened our existing dialogues with clinics, while also extending our reach to additional clinics. We are also receiving an increasing number of invites to various events and individual clinics,” says Palm.
In March, Inify signed an agreement with a supplier of logistic services – a leading global company in valuable transports, where safety and traceability are its core business. Such a partner will enable the company to keep full track of each and every tissue sample, from pick-up at the clinic to registration in the laboratory.
“This cross between two completely different industries is just another product of our innovative mindset. Any tissue sample picked up nationally will be delivered to our laboratory within 24 hours. In short, this is a partner that supports our customer promise of short, predictable turnaround times,” says Palm.
For further information, please contact CEO, Fredrik Palm, [email protected], or visit https://www.inify.com.
###
About Inify Laboratories
Inify Laboratories is currently building and establishing an ultramodern laboratory that will provide cancer diagnostics within histopathology. Designed from scratch, it uses a fully digital, standardized and AI-supported workflow to optimize quality and shorten response times, initially within prostate cancer. The first laboratory, located at Campus Solna Sweden, is estimated to start offering services to both public and private healthcare providers before summer 2023.
The company originates from ContextVision, with nearly 40 years of experience within digital imaging for medical applications and became independent through a spin-off in February 2022. The company, based in Sweden, is listed on Euronext Growth Oslo under the ticker INIFY.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.